SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.
SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.
复制标题
DOI：
10.1016/j.ajo.2020.08.030
复制
发表时间：
2021-03
影响因子：
4.2
通讯作者：
SCORE2 Investigator Group
中科院分区：
文献类型：
--
作者：
Hendrick A;VanVeldhuisen PC;Scott IU;King J;Blodi BA;Ip MS;Khurana RN;Oden NL;SCORE2 Investigator Group
To investigate the relationship between intraretinal macular hemorrhage and visual acuity outcomes in eyes with CRVO or HRVO managed with aflibercept, bevacizumab, or observation. Retrospective analysis of data from two randomized clinical trials. 362 participants were randomized in the Study of COmparative Treatments for REtinal Vein Occlusion 2 and 88 participants randomized to observation in the Standard Care versus COrticosteroid in REtinal Vein Occlusion Study. Participants received monthly intravitreal aflibercept or bevacizumab through Month 6 or observation through Month 8. Main outcome was visual acuity letter score (VALS). Reduced area of hemorrhage by Month 6 was observed in 70.7% (116/164) of aflibercept-treated eyes, 63.8% (104/163) of bevacizumab-treated eyes, and 42.2% (27/64) of observation eyes by Month 8 (P<0.01). Relative to eyes with hemorrhage during follow-up: aflibercept-treated eyes without hemorrhage at Month 6 had a mean VALS improvement of 8.0 (99% CI: 1.9, 14.2); bevacizumab-treated eyes without hemorrhage at Month 6 had a mean VALS improvement of 3.2 (99% CI: −4.6, 11.0); observation eyes without hemorrhage at Month 8 had a mean VALS improvement of 13.5 (99% CI: 0.4, 26.5). At Month 6, presence of hemorrhage and change in central subfield thickness (CST) were significantly associated with change in VALS; however, CST was a more important predictor. Improvement in hemorrhage during follow-up was associated with visual acuity improvements and predicted visual acuity changes beyond what was explained by CST. These findings suggest intraretinal macular hemorrhage is an important indicator of disease severity in retinal vein occlusion. This secondary analysis provides information on intraretinal macular hemorrhage changes in eyes with CRVO- or HRVO-associated macular edema treated with anti-VEGF injections or observation. Resolution of hemorrhages was associated with visual acuity improvement at Month 6. Hemorrhage status at Month 6 also independently predicted visual acuity changes at Month 6 beyond what was explained by changes in CST. These findings suggest intraretinal macular hemorrhage is an important indicator of disease severity in retinal vein occlusion.
登录
查看更多内容
DOI：
10.1001/archophthalmol.2010.193
发表时间：
2010-09
期刊：
Archives of ophthalmology (Chicago, Ill. : 1960)
影响因子：
--
作者：
Blodi BA;Domalpally A;Scott IU;Ip MS;Oden NL;Elledge J;Warren K;Altaweel MM;Kim JE;Van Veldhuisen PC;SCORE Study Research Group
通讯作者：
SCORE Study Research Group
影响因子：
8.1
作者：
Bressler, Neil M.;Beaulieu, Wesley T.;Wells, John A., III
通讯作者：
Wells, John A., III
影响因子：
13.7
作者：
Browning, David J.;Glassman, Adam R.;Miskala, Paivi H.
通讯作者：
Miskala, Paivi H.
影响因子：
13.7
作者：
Brown, David M.;Quan Dong Nguyen;Hopkins, J. Jill
通讯作者：
Hopkins, J. Jill
影响因子：
13.7
作者：
Brown, David M.;Campochiaro, Peter A.;Murahashi, Wendy Yee
通讯作者：
Murahashi, Wendy Yee